title: Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren's syndrome.
abstract: OBJECTIVE
  A new enzyme-linked immunosorbent assay for soluble CD4 (sCD4) and soluble CD8 (sCD8) molecules has been developed. We estimated the concentrations of these molecules in patients with Sjögren's syndrome and in patients with systemic lupus erythematosus (SLE) serving as a control population for non-Sjögren's inflammatory disease, since several findings suggestive of an aberration of immunocompetent cells have been reported in these autoimmune diseases.
  
  
  METHODS
  The study population consisted of 41 patients with Sjögren's syndrome (28 cases of the primary form and 13 cases of the secondary form), 66 patients with SLE, and 43 normal individuals. Serum samples and clinical and laboratory data were collected from each patient and control. Assays of the sCD4 and sCD8 molecules were performed using an enzyme-linked immunosorbent kit developed by T Cell Science Inc., Cambridge, MA.
  
  
  RESULTS
  The concentration of sCD4 was significantly increased in patients with both primary and secondary Sjögren's syndrome as compared with that in the control subjects. In contrast, sCD8 was significantly decreased in patients with primary disease but not in patients with secondary disease. A low or high concentration of sCD8 was significantly correlated with the presence of anti-SS-A antibody or hypocomplementemia, respectively. A similar significant correlation was noted between an increased sCD4 concentration and increased serum IgG level. In patients with SLE, the levels of both sCD4 and sCD8 were significantly increased.
  
  
  CONCLUSIONS
  These observations represent the first evidence of an increased level of the sCD4 molecule and a decreased level of the sCD8 molecule and an association with immunologic abnormalities in Sjögren's syndrome. The increased and decreased levels of these soluble molecules observed may play a pathologic role in patients with Sjögren's syndrome.
authors.affiliation: Department of Internal Medicine, Nerima Hikarigaoka Hospital, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Sawada
authors.forename: S
authors.initials: S
authors.lastname: Sugai
authors.forename: S
authors.initials: S
authors.lastname: Iijima
authors.forename: M
authors.initials: M
authors.lastname: Takei
authors.forename: E
authors.initials: E
authors.lastname: Paredes
authors.forename: T
authors.initials: T
authors.lastname: Hayama
authors.forename: S
authors.initials: S
authors.lastname: Nishinarita
authors.forename: Y
authors.initials: Y
authors.lastname: Hosokawa
authors.forename: T
authors.initials: T
authors.lastname: Horie
authors.forename: T
authors.initials: T
authors.lastname: Obara
mesh_terms: D000328:Adult; D000368:Aged; D015704:CD4 Antigens / Q000097:blood*; D016827:CD8 Antigens / Q000097:blood*; D016009:Chi-Square Distribution; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D016014:Linear Models; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology; D008875:Middle Aged; D012859:Sjogren's Syndrome / Q000276:immunology*; D012995:Solubility
chemical_list: D015704:CD4 Antigens; D016827:CD8 Antigens; D007136:Immunoglobulins